BBA
BLPH

Baker Bros. Advisors’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Baker Bros. Advisors’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-23,529
Closed -$1.83M – 137
2015
Q3 		$1.83M Buy
23,529
+196
+0.8% +$15.1K 0.02% 105
2015
Q2 		$2.78M Hold
23,333
– – 0.02% 93
2015
Q1 		$3.21M Buy
+23,333
New +$3.63M 0.03% 90

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Baker Bros. Advisors's BLPH Position: Q4 2015 in Review

Baker Bros. Advisors sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q4 2015, closing a stake of 23,529 shares — an estimated $1.83M sold.

Baker Bros. Advisors first reported a position in BLPH in Q1 2015 and held it in 3 quarters. The position peaked at $3.21M in Q1 2015. 14 funds tracked by Wall St. Rank hold BLPH as of Q4 2015.

  • Baker Bros. Advisors reported no remaining Bellerophon Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Baker Bros. Advisors sold 23,529 Bellerophon Therapeutics, Inc. shares in Q4 2015, an estimated $1.83M.
  • Baker Bros. Advisors first reported a position in Bellerophon Therapeutics, Inc. in Q1 2015 and held it in 3 quarters.
  • Baker Bros. Advisors's Bellerophon Therapeutics, Inc. position peaked at $3.21M in Q1 2015.
  • 14 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q4 2015.

Based on Baker Bros. Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.